Published April 27, 2026 | Version v1
Journal article Open

Africa cannot afford to wait for malaria treatment failure

Authors/Creators

  • 1. Independent consultant, Germany
  • 2. London School of Hygiene and Tropical Medicine, UK
  • 3. Ifakara Health Institute and National Institute for Medical Research, Tanzania
  • 4. Impact Santé Afrique, Cameroon
  • 5. London School of Hygiene and Tropical Medicine, UK; Malaria Elimination Initiative, Institute of Global Health Science, University of California San Francisco, USA

Description

For more than two decades, artemisinin-based combination therapies (ACTs) have been the backbone of malaria treatment across Africa. They have saved millions of lives and averted many malaria cases. That foundation is now under threat. Artemisinin partial resistance (ART-R) is now being detected using molecular surveillance across eastern Africa, the Horn of Africa, and southern Africa. It has already been confirmed in four countries: Rwanda, Uganda, Eritrea and Tanzania, with signals reported in several neighbouring countries [1].

Files

Pindolia et al. HardTalk_MWJ2026_17_9.pdf

Files (1.2 MB)

Name Size Download all
md5:69f5492baf0714e7f7480b82d50ce9a9
1.2 MB Preview Download

Additional details

Identifiers

Other
PMC13135355